Physician profile
Mindy Griffith
NPI 1487997821
$806.23
in general payments reported to CMS, 2019-2025
15 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $103 · 2021: $68.87 · 2022: $133 · 2023: $208 · 2024: $192 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.85 | 2020-2024 | Wegovy |
| Lilly USA, LLC | $167.56 | 2020-2023 | Mounjaro, Trulicity, Humulin |
| Medtronic, INC. | $98.75 | 2021-2023 | Minimed 670g |
| Merck Sharp & Dohme LLC | $74.17 | 2020-2025 | Verquvo |
| Amgen INC. | $49.99 | 2025 | Evenity |
| Xeris Pharmaceuticals, INC. | $49.38 | 2023-2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $28.20 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $23.91 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ardelyx, INC. | $21.99 | 2025 | Ibsrela |
| Dexcom, INC. | $19.99 | 2021 | |
| Mannkind Corporation | $16.99 | 2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.91 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $15.46 | 2022 | |
| Insulet Corporation | $13.75 | 2025 | Omnipod |
| Medtronic Minimed, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.